Clinical Trial Update: Fexofenadine HCl 180 mg, Montelukast Sodium 10 mg and Placebo in Suppression of Wheal and Flare Induced by Seasonal Allergen [Phase 4]

View source ↗

Summary

Phase 4 trial evaluating whether fexofenadine HCl 180 mg plus montelukast sodium 10 mg reduces wheal and flare responses to seasonal allergens in allergic rhini…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Allergic Rhinitis

Drugs mentioned

• Fexofenadine HCl 180 mg (fexofenadine)
• Montelukast Sodium 10 mg (Montelukast)

Snippet

Sponsor: Sanofi | Conditions: Allergic Rhinitis | Phase 4 | Status: COMPLETED